Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology & Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DGKA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DGKA Recombinant Protein (Full-Length & Catalytic Domain). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View DGKA Products |
| Mutant Panel | DGKA Kinase-Dead Mutants (D475A/D477A) and disease-associated variant (rs17852990). For selectivity counter-screening and resistance studies. | View DGKA Products |
| Gene Delivery | DGKA Promise-ORF / Lentivirus. Full-length ORF for stable overexpression in T cells or tumor lines. | View DGKA Products |
| Detection Ab | Anti-DGKA Recombinant Antibody (Rabbit/Mouse monoclonal or polyclonal). Suitable for WB, IP, ICC. | View DGKA Products |
| Validator | DGKA siRNA Set (3 target-specific duplexes + scrambled control). For knockdown verification and specificity confirmation. | View DGKA Products |
| Related Target A | DGKB (Diacylglycerol Kinase Beta). Close paralog for selectivity profiling. | View DGKB Products |
| Related Target B | DGKZ (Diacylglycerol Kinase Zeta). Immune-related isoform; dual inhibition enhances T-cell activation. | View DGKZ Products |
| Related Target C | RASGRP1 (RAS Guanyl-Releasing Protein 1). DAG-Ras pathway node; functional rescue assay biomarker. | View RASGRP1 Products |
| Related Target D | PDCD1 (PD-1). Combination therapy rationale for reversing T-cell exhaustion. | View PDCD1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Biochemical enzymatic assay & active site integrity | Recombinant DGKA >95% purity, Sequence Verified, Theoretical MW confirmed by Mass Spec. Endotoxin <1EU/ug. Includes kinase-dead mutants as negative controls. |
| Isoform selectivity (DGKB, DGKZ, DGKG, DGKQ counter-screen) | Full-length panel of DGKA, DGKB, DGKZ, DGKQ strictly verified by sequence identity and mass spec; available for cross-reactivity profiling. |
| Cellular target engagement & DAG accumulation | Full-length DGKA Lentivirus + siRNA validator for gain- and loss-of-function studies in native cell lines. Cellular thermal shift assay (CETSA) enabled via stable lines. |
| Off-target kinase inhibition & false positive mitigation | Benchmark antibody + validated siRNA controls included for orthogonal target confirmation. Kinome-wide counter-screening supported. |
Live DGKA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DGKA-targeted therapeutics is intensifying at the preclinical frontier. DGKA (diacylglycerol kinase alpha) acts as a critical metabolic checkpoint in T-cell receptor signaling: it converts DAG to PA, dampening PKC activation and promoting T-cell anergy. The field is rapidly pivoting from broad pan-DGK inhibitors to highly selective DGKA modulators to minimize neurological and hepatic toxicity. Emerging strategies include dual DGKA/DGKZ inhibition to overcome functional redundancy, and rational combinations with immune checkpoint blockades (e.g., anti-PD-1) to reverse T-cell exhaustion in cold tumors. First-generation selective inhibitors are expected to enter Phase I clinical trials in 2026–2027, targeting T-cell lymphomas, solid tumors (immuno-oncology), and autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor (Allosteric/Active Site) | AstraZeneca, Novartis, early-stage biotechs, academic consortia | T-cell lymphoma, solid tumors (IO), autoimmune disease | Kinase activity assay (radioactive/fluorescent DAG conversion); selectivity panel vs DGKB/DGKZ/DGKQ |
| PROTAC / Degrader | Discovery-stage programs, emerging biotechs | Hematologic malignancies, refractory cancers | Target engagement (cellular) and degradation validation using lentivirus-expressed DGKA lines and specific antibodies |
| Genetic Modulation | Academic research centers | Immuno-oncology | Lentivirus and validated siRNA for KO/KD rescue and DAG-level phenotyping |
| Combination Therapy (IO) | Merck, BMS, research collaborations | CAR-T enhancement, PD-1 refractory tumors (melanoma, NSCLC) | T-cell activation assay (NFAT reporter), cytokine release profiling; siRNA validation controls essential |
Molecular Differentiation & Assay Strategy
To achieve best-in-class DGKA inhibitors, developers must address several molecular differentiation factors:
-
Isoform Selectivity: DGKA shares high catalytic-domain homology with DGKB, DGKZ, and DGKH. A >100-fold (ideally >500-fold) selectivity window is required to avoid neurotoxicity (DGKZ in CNS) and off-target effects. Assay need: Full-length panel screening (DGKA, DGKB, DGKZ, DGKQ) with IC50 shift assays.
-
Allosteric vs Active-Site Inhibition: Active-site inhibitors may suffer from high conservation; allosteric modulation can achieve better selectivity but requires conformation-sensitive proteins. Assay need: Orthogonal validation using kinase-dead mutants (D475A/D477A) as negative controls; surface plasmon resonance (SPR) and differential scanning fluorimetry (DSF) for binding site elucidation.
-
Cell Permeability & Target Engagement: DGKA is intracellular; compounds must penetrate the membrane. Assay need: Cellular thermal shift assay (CETSA) using lentivirus-stable cell lines; siRNA rescue experiments to confirm on-target mechanism.
-
Functional Phenotyping: Biochemical activity may not correlate with cellular function. Assay need: NFAT luciferase reporter assay in Jurkat T cells, flow cytometry for CD69/CD25, and cytokine profiling (IFN-γ, IL-2).
TarMart offers the complete toolkit: high-purity active WT and mutant proteins (including the disease-associated variant rs17852990), full isoform panels, kinase-dead controls, validated siRNAs, and lentiviral ORFs for both wild-type and mutant DGKA. Low endotoxin (<1EU/ug) ensures compatibility with sensitive immune cell assays.